Trends in Management of Osteoporosis Following Primary Vertebral Compression Fracture

Overview

Journal J Endocr Soc

Specialty Endocrinology

Date 2023 Jun 30

PMID 37388575

Authors

Karen Malacon

Isidora Beach

Gavin Touponse

Taiyeb Rangwalla

Jennifer Lee

Corinna Zygourakis

Affiliations

Soon will be listed here.

Abstract

Purpose: Osteoporosis affects more than 200 million individuals worldwide and predisposes to vertebral compression fractures (VCFs). Given undertreatment of fragility fractures, including VCFs, we investigate current anti-osteoporotic medication prescribing trends.

Methods: Patients 50 and older with a diagnosis of primary closed thoracolumbar VCF between 2004 and 2019 were identified from the Clinformatics® Data Mart database. Multivariate analysis was performed for demographic and clinical treatment and outcome variables.

Results: Of 143 081 patients with primary VCFs, 16 780 (11.7%) were started on anti-osteoporotic medication within a year; 126 301 (88.3%) patients were not started on medication. The medication cohort was older (75.4 ± 9.3 vs 74.0 ± 12.3 years, < .001), had higher Elixhauser Comorbidity Index scores (4.7 ± 6.2 vs 4.3 ± 6.7, < .001), was more likely to be female (81.1% vs 64.4%, < .001), and was more likely to have a formal osteoporosis diagnosis (47.8% vs 32.9%) than the group that did not receive medication. Alendronate (63.4%) and calcitonin (27.8%) were the most commonly initiated medications. The proportion of individuals receiving anti-osteoporotic medication within the year following VCF peaked in 2008 (15.2%), then declined until 2012 with a modest increase afterward.

Conclusions: Osteoporosis remains undertreated after low-energy VCFs. New anti-osteoporotic medication classes have been approved in recent years. Bisphosphonates remain the most prescribed class. Increasing recognition and treatment of osteoporosis is paramount to decreasing the risk of subsequent fractures.

Citing Articles

Impact of the guidance on fracture Liaison Services and the introduction of a new fee for secondary fracture prevention in Japan: Implementation of secondary fracture prevention during hospitalization for fragility fractures.

Gondo G, Shin J, Kunisawa S, Imanaka Y Osteoporos Int. 2024; 36(2):235-244.

PMID: 39671048 PMC: 11825641. DOI: 10.1007/s00198-024-07269-0.

The Fracture Phenotypes in Women and Men of 50 Years and Older with a Recent Clinical Fracture.

Geusens P, van den Bergh J, Roux C, Chapurlat R, Center J, Bliuc D Curr Osteoporos Rep. 2024; 22(6):611-620.

PMID: 39254815 DOI: 10.1007/s11914-024-00885-z.

Unrecognized and Undertreated Vertebral Fractures: What Else We Must Do.

Rao S J Endocr Soc. 2023; 7(12):bvad139.

PMID: 38024649 PMC: 10661655. DOI: 10.1210/jendso/bvad139.

Trends in Management of Osteoporosis Following Primary Vertebral Compression Fracture.

Malacon K, Beach I, Touponse G, Rangwalla T, Lee J, Zygourakis C J Endocr Soc. 2023; 7(7):bvad085.

PMID: 37388575 PMC: 10306270. DOI: 10.1210/jendso/bvad085.

References

Wysowski D, Greene P . Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012. Bone. 2013; 57(2):423-8. DOI: 10.1016/j.bone.2013.09.008. View

Wadhwa H, Wu J, Lee J, Zygourakis C . Anabolic and Antiresorptive Osteoporosis Treatment: Trends, Costs, and Sequence in a Commercially Insured Population, 2003-2021. JBMR Plus. 2023; 7(10):e10800. PMC: 10556263. DOI: 10.1002/jbm4.10800. View

Barton D, Behrend C, Carmouche J . Rates of osteoporosis screening and treatment following vertebral fracture. Spine J. 2018; 19(3):411-417. DOI: 10.1016/j.spinee.2018.08.004. View

Chua W, Nandi N, Masud T . Pharmacological treatments for osteoporosis in very elderly people. Ther Adv Chronic Dis. 2012; 2(4):279-86. PMC: 3513886. DOI: 10.1177/2040622311409972. View

Boonen S, McClung M, Eastell R, Fuleihan G, Barton I, Delmas P . Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc. 2004; 52(11):1832-9. DOI: 10.1111/j.1532-5415.2004.52506.x. View

Johnell O, Kanis J . Epidemiology of osteoporotic fractures. Osteoporos Int. 2004; 16 Suppl 2:S3-7. DOI: 10.1007/s00198-004-1702-6. View

Farmer R, Herbert B, Cuellar D, Hao J, Stahel P, Yasui R . Osteoporosis and the orthopaedic surgeon: basic concepts for successful co-management of patients' bone health. Int Orthop. 2014; 38(8):1731-8. PMC: 4115108. DOI: 10.1007/s00264-014-2317-y. View

Wickham R . Cholecalciferol and Cancer: Is It a Big D3-eal?. J Adv Pract Oncol. 2014; 3(4):249-57. PMC: 4093346. DOI: 10.6004/jadpro.2012.3.4.6. View

Hiligsmann M, Cornelissen D, Vrijens B, Abrahamsen B, Al-Daghri N, Biver E . Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and.... Osteoporos Int. 2019; 30(11):2155-2165. PMC: 6811382. DOI: 10.1007/s00198-019-05104-5. View

10.

Balkhi B, Seoane-Vazquez E, Rodriguez-Monguio R . Changes in the utilization of osteoporosis drugs after the 2010 FDA bisphosphonate drug safety communication. Saudi Pharm J. 2018; 26(2):238-243. PMC: 6111194. DOI: 10.1016/j.jsps.2017.12.005. View

11.

Malik A, Retchin S, Phillips F, Xu W, Peters K, Yu E . Declining trend in osteoporosis management and screening following vertebral compression fractures - a national analysis of commercial insurance and medicare advantage beneficiaries. Spine J. 2019; 20(4):538-546. DOI: 10.1016/j.spinee.2019.10.020. View

12.

Cummings S, Black D, Thompson D, Applegate W, Barrett-Connor E, Musliner T . Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1999; 280(24):2077-82. DOI: 10.1001/jama.280.24.2077. View

13.

Haffner M, Delman C, Wick J, Han G, Roberto R, Javidan Y . Osteoporosis Is Undertreated After Low-energy Vertebral Compression Fractures. J Am Acad Orthop Surg. 2021; 29(17):741-747. DOI: 10.5435/JAAOS-D-20-01132. View

14.

Turk J, Deaton A, Yin J, Stolina M, Felx M, Boyd G . Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture. Regul Toxicol Pharmacol. 2020; 115:104697. DOI: 10.1016/j.yrtph.2020.104697. View

15.

Cosman F, de Beur S, LeBoff M, Lewiecki E, Tanner B, Randall S . Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014; 25(10):2359-81. PMC: 4176573. DOI: 10.1007/s00198-014-2794-2. View

16.

. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994; 843:1-129. View

17.

Yeam C, Chia S, Tan H, Kwan Y, Fong W, Seng J . A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporos Int. 2018; 29(12):2623-2637. DOI: 10.1007/s00198-018-4759-3. View

18.

Sardar Z, Coury J, Cerpa M, DeWald C, Ames C, Shuhart C . Best Practice Guidelines for Assessment and Management of Osteoporosis in Adult Patients Undergoing Elective Spinal Reconstruction. Spine (Phila Pa 1976). 2021; 47(2):128-135. DOI: 10.1097/BRS.0000000000004268. View

19.

van Walraven C, Austin P, Jennings A, Quan H, Forster A . A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009; 47(6):626-33. DOI: 10.1097/MLR.0b013e31819432e5. View

20.

Wysowski D . Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009; 360(1):89-90. DOI: 10.1056/NEJMc0808738. View